Early this week Khiron Life Sciences Corp. (TSXV:KHRN) closed at a record daily high. This followed three recent such events that have showed the continuous growth of the company’s share price.
Khiron is a vertically-integrated medical cannabis company fully licensed to conduct its core operations in Colombia. The first Colombia-based cannabis company to be listed on the TSXV, Khiron Life Sciences is also positioned as a first mover in the most advanced regulatory environment in Latin America.
In a recent article on their site, Midas Letter provided insight and commentary into the stock’s progress, suggesting the trajectory stands in contrast to the rest of the junior cannabis market. Standing out among its peers, Khiron’s management team is embellished by the likes of former DEA Supervisor Matt Murphy, CEO Alvaro Torres, previously serving SNC-Lavalin Colombia, and former Mexican president Vicente Fox. Khiron is also uniquely a pure-play Latin American operation, which is spurring the interest of other larger licensed producers looking to enter that jurisdiction.
The company’s value was also recently affirmed in initial coverage from Cannacord Genuity, which gave Khiron a ‘speculative buy’ rating of $3.00. The major Canadian investment bank also suggested that Khiron trades at approximately an 80 percent discount to the average of its Canadian peers. Cannacord also suggested that Khiron is trading at a “valuation discount compared to recent peer [Latin American] transactions.”
Looking forward, Cannacord believes that by implementing a business model that focuses on distribution to clinics and the medical community, Khiron is pursuing a higher-margin opportunity that could lead to a gross margin percentage in the mid forties.
To read the full article, click here.